ADDERALL XR
®
(mixed salts amphetamine extended-release capsules) Page 10 of 43
2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/day on a mg/m
2
body surface area basis.
Amphetamine, in the enantiomer ratio present in ADDERALL XR (d- to l- ratio of 3:1), was not clastogenic
in the mouse bone marrow micronucleus test in vivo and was negative when tested in the E. coli
component of the Ames test in vitro. d,l-amphetamine (1:1 enantiomer ratio) has been reported to
produce a positive response in the mouse bone marrow micronucleus test, an equivocal response in the
Ames test, and negative responses in the in vitro sister chromatid exchange and chromosomal
aberration assays.
Cardiovascular
Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems and Sudden Death
Children/Adolescents: Sudden death has been reported with sympathomimetic drugs used for ADHD
treatment at therapeutic doses in children/adolescents with structural cardiac abnormalities or other
serious heart problems. Although some serious heart problems alone carry an increased risk of sudden
death, ADDERALL XR (mixed salts amphetamine extended-release capsules) generally should not be
used in children/adolescents with known serious structural cardiac abnormalities or other serious heart
problems (e.g., cardiomyopathy, serious heart rhythm abnormalities) that may place them at increased
vulnerability to the sympathomimetic effects of ADHD drugs (see 2 CONTRAINDICATIONS).
Adults: Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant
drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown,
adults have a greater likelihood than children of having serious structural cardiac abnormalities,
cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac
problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (see
2 CONTRAINDICATIONS).
Children: Theoretically there exists a pharmacological potential for all ADHD drugs to increase the risk of
sudden/cardiac death. Although confirmation of an incremental risk for adverse cardiac events arising
from treatment with ADHD medications is lacking, prescribers should consider this potential risk.
Hypertension and other Cardiovascular Conditions
Sympathomimetic medications can cause a modest increase in average blood pressure and average
heart rate and individuals may have larger increases. While the mean changes alone would not be
expected to have short-term consequences, all patients should be monitored for larger changes in heart
rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions
might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing
hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia (see 2
CONTRAINDICATIONS). Blood pressure and pulse should be monitored at appropriate intervals in
patients taking ADDERALL XR, especially patients with hypertension.
All drugs with sympathomimetic effects prescribed in the management of ADHD should be used with
caution in patients who: a) are involved in strenuous exercise or activities b) use other sympathomimetic
drugs or c) have a family history of sudden/cardiac death. Prior to the initiation of treatment with
sympathomimetic medications, a personal and family history (including assessment for a family history
of sudden death or ventricular arrhythmia) and physical exam should be obtained to assess for the
presence of cardiac disease. In patients with relevant risk factors and based on the clinician’s judgment,
further cardiovascular evaluation may be considered (e.g., electrocardiogram and echocardiogram).
Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms
suggestive of cardiac disease during ADHD treatment should undergo a prompt cardiac evaluation.